Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open-Label, Multiple-Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Coadministration of BMS-650032, BMS-790052, and BMS-791325 When Administered for 24 or 12 Weeks in Treatment-Naïve Subjects Infected With Hepatitis C Virus Genotype 1
Brief Summary: The purpose of this study is to estimate the rate of sustained virologic response (SVR) SVR12, where SVR12 is defined as HCV RNA \< LOQ (detectable or undetectable) 12 weeks post-treatment in Genotype 1 \& Genotype 4 treatment naive patients, and Genotype (GT1) infected patients who are prior null responders to pegIFN/ribavirin


Options:
A: Arm Label: SOF+PEG+RBV 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Arm Label: SOF+PEG+RBV 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Arm Label: SOF+PEG+RBV 12 week/Rerandomization Group; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): SOF+PEG+RBV 12 week/Rerandomization Group, SOF+PEG+RBV 12 weeks, SOF+PEG+RBV 24 weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+PEG+RBV 12 week/Rerandomization Group, SOF+PEG+RBV 12 weeks, SOF+PEG+RBV 24 weeks | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): SOF+PEG+RBV 12 week/Rerandomization Group, SOF+PEG+RBV 12 weeks, SOF+PEG+RBV 24 weeks
B: Arm Label: Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV; Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325, Drug: Ribavirin | Intervention Type: DRUG; Name: BMS-650032; Assigned to Arm(s): Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV | Intervention Type: DRUG; Name: BMS-790052; Assigned to Arm(s): Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV
C: Arm Label: Group A: T12/PR48; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Arm Label: Group B: T12(DS)/PR48; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Arm Label: Group C: Pbo/PR48; Type: EXPERIMENTAL; Interventions: Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48 | Intervention Type: DRUG; Name: Peg-IFN-alfa-2a; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48
D: Arm Label: T12PR24 (eRVR+); Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon alfa-2a | Arm Label: T12PR48 (eRVR+); Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon alfa-2a | Arm Label: T12PR48 (eRVR-); Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon alfa-2a | Arm Label: Other; Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon alfa-2a | Intervention Type: DRUG; Name: telaprevir; Assigned to Arm(s): Other, T12PR24 (eRVR+), T12PR48 (eRVR+), T12PR48 (eRVR-) | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Other, T12PR24 (eRVR+), T12PR48 (eRVR+), T12PR48 (eRVR-) | Intervention Type: BIOLOGICAL; Name: peginterferon alfa-2a; Assigned to Arm(s): Other, T12PR24 (eRVR+), T12PR48 (eRVR+), T12PR48 (eRVR-)

Answer: B